Fast Five Quiz: Secondary Prevention of Cardiovascular Disease

Yasmine S. Ali, MD


December 14, 2020

Treatment with NSAIDs in patients with prior MI, whether short term or long term, has been associated with increased risk for death and recurrent MI in patients with prior MI and should be avoided in this population.

All patients who smoke should be encouraged to quit smoking at each visit and provided with counseling, nicotine replacement, and other pharmacotherapy as indicated in conjunction with a behavioral program or formal smoking cessation program.

Lipid-lowering therapies are important for secondary prevention of CVD, including among patients with chronic kidney disease. Results from the SHARP trial suggest that combination cholesterol-lowering therapy safely reduces the incidence of major atherosclerotic events in a broad range of patients with advanced chronic kidney disease.

Unless contraindicated, ACE inhibitor therapy should be initiated and continued indefinitely in all patients with an LVEF ≤ 40%, as well as in patients with hypertension, diabetes, or chronic kidney disease.

Learn more about secondary prevention of CVD.


Comments on Medscape are moderated and should be professional in tone and on topic. You must declare any conflicts of interest related to your comments and responses. Please see our Commenting Guide for further information. We reserve the right to remove posts at our sole discretion.